Glenmark Launches Methylene Blue Injection in US Market; Shares Edge Higher

Mumbai, June 17: Glenmark Pharmaceuticals Ltd’s US subsidiary has launched Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial in the United States, further expanding the company’s institutional and injectable product portfolio in one of its key overseas markets.

The newly launched product is bioequivalent and therapeutically equivalent to Provepharm SAS’ reference listed drug, ProvayBlue Injection, according to the company.

The launch targets a niche but established market. Citing IQVIA data, Glenmark said the reference product recorded annual sales of approximately $19 million in the United States during the 12 months ended April 2026.

While the opportunity may not be among the company’s largest generic launches, it strengthens Glenmark’s presence in the injectable medicines segment, an area that typically carries higher entry barriers and fewer competitors than conventional oral formulations.

Marc Kikuchi, President and Business Head, North America at Glenmark, said the launch reflects the company’s focus on expanding access to affordable medicines while reinforcing its institutional portfolio in the US healthcare market.

Stock Market Snapshot

Glenmark share price remained modestly higher in morning trade following the announcement.

As of 9:53 AM IST on June 17, 2026, shares of Glenmark Pharmaceuticals Ltd were trading at ₹2,159.50, up ₹2.80 or 0.13% from the previous close.

The muted reaction suggests investors largely viewed the launch as an incremental addition to the company’s US portfolio rather than a near-term earnings game changer. However, product launches remain a closely watched metric for pharmaceutical companies as they contribute to long-term revenue diversification and market share gains.

The Glenmark share price has been in focus this year amid continued developments across its branded, generic and specialty pharmaceutical businesses.

US Remains a Key Growth Market

For Indian pharmaceutical companies, the United States continues to be the world’s most lucrative generic drug market despite ongoing pricing pressures.

Companies have increasingly shifted focus towards complex generics, injectables and specialty products where competition is relatively lower and margins tend to be more resilient.

Glenmark has been steadily broadening its US product basket through new approvals and launches while also investing in innovation-led therapies across respiratory, dermatology and oncology segments.

The latest launch aligns with that strategy by adding another differentiated injectable product to its North American portfolio.

Company Background

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with operations across branded formulations, generics and specialty medicines.

The company has 11 manufacturing facilities worldwide and maintains a commercial presence in more than 80 countries. Its portfolio spans respiratory, dermatology, oncology and consumer healthcare products.

Glenmark is also pursuing innovation-led drug development alongside its core generics business, with a focus on improving access to affordable medicines across global markets.

Conclusion

The launch of Methylene Blue Injection USP strengthens Glenmark’s injectable portfolio in the United States and provides access to a market estimated at around $19 million annually.

While the financial impact is likely to be gradual, the launch underscores Glenmark’s continued focus on expanding its presence in complex and institutional pharmaceutical segments, a strategy that remains central to its long-term growth ambitions.

Source:

• https://www.nseindia.com/get-quote/equity/GLENMARK/Glenmark-Pharmaceuticals-Limited
• https://nsearchives.nseindia.com/corporate/GLENMARK_17062026083722_PR_BSE_NSE_17062026.pdf